Keynote review: Chromatin control and cancer-drug discovery: Realizing the promise

Drug Discovery Today

Volumn 11, Issue 3-4, 2006, Pages 97-109

  Inche, Adam G ^c   La Thangue, Nicholas B ^a,b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b The Royal College of Physicians of Edinburgh   (United Kingdom)

^c EMBO ^*

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; BUTYRIC ACID; CHROMATIN MODULATING DRUG; DNA METHYLTRANSFERASE INHIBITOR; FR 901228; GARCINOL; HESPERADIN; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; METHYLTRANSFERASE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN LYSINE METHYLTRANSFERASE; RETINOIC ACID; SUBEROYLANILIDE HYDROXAMIC ACID; TRICHSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VX 680;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CHROMATIN; CLINICAL TRIAL; DNA METHYLATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; EPIGENETICS; EPILEPSY; GENE EXPRESSION REGULATION; HUMAN; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROTEIN MODIFICATION; REVIEW; DRUG ANTAGONISM; DRUG DESIGN; GENETICS; METABOLISM; NEOPLASM; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CHROMATIN; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; METHYLTRANSFERASES; NEOPLASMS; PHOSPHORYLATION;

EID: 33644872992     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03691-3     Document Type: Review

References (161)

1. Chakravarthy S. Structure and dynamic properties of nucleosome core particles FEBS Lett. 579 2005 895 898
2. Fernandez-Capetillo O. H2AX: the histone guardian of the genome DNA Repair (Amst.) 3 2004 959 967
3. Reeves R. HMGA proteins: flexibility finds a nuclear niche? Biochem. Cell Biol. 81 2003 185 195
4. Agresti A., Bianchi M.E. HMGB proteins and gene expression Curr. Opin. Genet. Dev. 13 2003 170 178
5. Peterson C.L. Chromatin remodeling enzymes: taming the machines. Third in review series on chromatin dynamics EMBO Rep. 3 2002 319 322
6. Lusser A., Kadonaga J.T. Chromatin remodeling by ATP-dependent molecular machines Bioessays 25 2003 1192 1200
7. Strahl B.D., Allis C.D. The language of covalent histone modifications Nature 403 2000 41 45
8. Peterson C.L., Laniel M-A. Histones and histone modifications Curr. Biol. 14 2004 R546
9. de la Cruz X. Do protein motifs read the histone code? Bioessays 27 2005 164 175
10. Berger S.L. Histone modifications in transcriptional regulation Curr. Opin. Genet. Dev. 12 2002 142 148
11. Marmorstein R. Protein modules that manipulate histone tails for chromatin regulation Nat. Rev. Mol. Cell Biol. 2 2001 422 432
12. Yang X.J. Lysine acetylation and the bromodomain: a new partnership for signaling Bioessays 26 2004 1076 1087
13. Marmorstein R. Structure of histone acetyltransferases J. Mol. Biol. 311 2001 433 444
14. Letunic I. SMART 4.0: towards genomic data integration Nucleic Acids Res. 32 2004 D142 D144 (Database issue)
15. Schultz J. SMART, a simple modular architecture research tool: identification of signaling domains Proc. Natl. Acad. Sci. U. S. A. 95 1998 5857 5864
16. Brehm A. The many colours of chromodomains Bioessays 26 2004 133 140
17. Moore J.D., Krebs J.E. Histone modifications and DNA double-strand break repair Biochem. Cell Biol. 82 2004 446 452
18. Wang C. Histone acetylation/deacetylation as a regulator of cell cycle gene expression Methods Mol. Biol. 241 2004 207 216
19. Eckhardt R.A. Chromatin and chromosome structure 1977 Academic Press
20. Hebbes T.R. A direct link between core histone acetylation and transcriptionally active chromatin EMBO J. 7 1988 1395 1402
21. Allan J. Participation of core histone "tails" in the stabilization of the chromatin solenoid J. Cell Biol. 93 1982 285 297
22. Hansen J.C. Structure and function of the core histone N- termini: more than meets the eye Biochemistry 37 1998 17637 17641
23. Kalkhoven E. CBP and p300: HATs for different occasions Biochem. Pharmacol. 68 2004 1145 1155
24. Chan H.M., La Thangue N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds J. Cell Sci. 114 2001 2363 2373
25. Wang H.G. Identification of specific adenovirus E1A N- terminal residues critical to the binding of cellular proteins and to the control of cell growth J. Virol. 67 1993 476 488
26. Stein R.W. Analysis of E1A-mediated growth regulation functions: binding of the 300-kilodalton cellular product correlates with E1A enhancer repression function and DNA synthesis-inducing activity J. Virol. 64 1990 4421 4427
27. Chrivia J.C. Phosphorylated CREB binds specifically to the nuclear protein CBP Nature 365 1993 855 859
28. Borrow J. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein Nat. Genet. 14 1996 33 41
29. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases Nucleic Acids Res. 32 2004 959 976
30. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors Microbiol. Mol. Biol. Rev. 64 2000 435 459
31. Deguchi K. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2- mediated recruitment of CBP Cancer Cell 3 2003 259 271
32. Ernst P. MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein Mol. Cell. Biol. 21 2001 2249 2258
33. Lavau C. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia EMBO J. 19 2000 4655 4664
34. Sobulo O.M. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3) Proc. Natl. Acad. Sci. U. S. A. 94 1997 8732 8737
35. Taki T. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene Blood 89 1997 3945 3950
36. Iyer N.G. p300/CBP and cancer Oncogene 23 2004 4225 4231
37. Grossman S.R. p300/CBP/p53 interaction and regulation of the p53 response Eur. J. Biochem. 268 2001 2773 2778
38. Rubinstein J.H. Broad thumb-hallux (Rubinstein-Taybi) syndrome 1957-1988 Am. J. Med. Genet. Suppl. 6 1990 3 16
39. Petrij F. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP Nature 376 1995 348 351
40. Miller R.W., Rubinstein J.H. Tumors in Rubinstein-Taybi syndrome Am. J. Med. Genet. 56 1995 112 115
41. Louie M.C. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance Mol. Cell. Biol. 24 2004 5157 5171
42. Schiltz R.L., Nakatani Y. The PCAF acetylase complex as a potential tumor suppressor Biochim. Biophys. Acta 1470 2000 M37 M53
43. Nishimori H. Analysis of the p300/CBP-Associated Factor (PCAF) gene in astrocytic tumors J. Neurooncol. 46 2000 17 22
44. Gregoretti I.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J. Mol. Biol. 338 2004 17 31
45. Yang X.J., Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication Mol. Cell. Biol. 25 2005 2873 2884
46. Marmorstein R. Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases Biochem. Soc. Trans. 32 2004 904 909
47. L. Gao Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family J. Biol. Chem. 277 2002 25748 25755
48. Laherty C.D. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression Cell 89 1997 349 356
49. David G. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein Oncogene 16 1998 2549 2556
50. Meehan W.J. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription J. Biol. Chem. 279 2004 1562 1569
51. Glaser K.B. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol. Cancer Ther. 2 2003 151 163
52. P. Zhu Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis Cancer Cell 5 2004 455 463
53. Weston A.D. Active repression by unliganded retinoid receptors in development: less is sometimes more J. Cell Biol. 161 2003 223 228
54. Warrell R.P. Jr Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid) N. Engl. J. Med. 324 1991 1385 1393
55. Huang M.E. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia Blood 72 1988 567 572
56. Guidez F. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient Leukemia 8 1994 312 317
57. Brehm A. Retinoblastoma protein recruits histone deacetylase to repress transcription Nature 391 1998 597 601
58. Ferreira R. Cell cycle-dependent recruitment of HDAC-1 correlates with deacetylation of histone H4 on an Rb-E2F target promoter EMBO Rep. 2 2001 794 799
59. Verdin E. Class II histone deacetylases: versatile regulators Trends Genet. 19 2003 286 293
60. Belinsky S.A. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer Cancer Res. 63 2003 7089 7093
61. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer Nat. Rev. Genet. 3 2002 415 428
62. Das P.M., Singal R. DNA methylation and cancer J. Clin. Oncol. 22 2004 4632 4642
63. Ohtani-Fujita N. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene Oncogene 8 1993 1063 1067
64. Feinberg A.P., Tycko B. The history of cancer epigenetics Nat. Rev. Cancer 4 2004 143 153
65. Jones P.L. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription Nat. Genet. 19 1998 187 191
66. Cameron E.E. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat. Genet. 21 1999 103 107
67. Kouzarides T. Histone methylation in transcriptional control Curr. Opin. Genet. Dev. 12 2002 198 209
68. Schneider R. Unsafe SETs: histone lysine methyltransferases and cancer Trends Biochem. Sci. 27 2002 396 402
69. Cheung P., P. Lau Epigenetic regulation by histone methylation and histone variants Mol. Endocrinol. 19 2005 563 573
70. Stewart M.D. Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment Mol. Cell. Biol. 25 2005 2525 2538
71. R. Cao, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3 Curr. Opin. Genet. Dev. 14 2004 155 164
72. Kleer C.G. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc. Natl. Acad. Sci. U. S. A. 100 2003 11606 11611
73. Sellers W.R., Loda M. The EZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer? Cancer Cell 2 2002 349 350
74. Sudo T. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma Br. J. Cancer 92 2005 1754 1758
75. Tang X. Activated p53 suppresses the histone methyltransferase EZH2 gene Oncogene 23 2004 5759 5769
76. Sims R.J. 3rd Histone lysine methylation: a signature for chromatin function Trends Genet. 19 2003 629 639
77. Hess J.L. MLL: a histone methyltransferase disrupted in leukemia Trends Mol. Med. 10 2004 500 507
78. Aagaard L. Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-9 encode centromere-associated proteins which complex with the heterochromatin component M31 EMBO J. 18 1999 1923 1938
79. Schotta G. SU(VAR)3-9 is a conserved key function in heterochromatic gene silencing Genetica 117 2003 149 158
80. Nielsen S.J. Rb targets histone H3 methylation and HP1 to promoters Nature 412 2001 561 565
81. Peters A.H. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability Cell 107 2001 323 337
82. Braig M. Oncogene-induced senescence as an initial barrier in lymphoma development Nature 436 2005 660 665
83. Derunes C. Characterization of the PR domain of RIZ1 histone methyltransferase Biochem. Biophys. Res. Commun. 333 2005 925 934
84. Kim K.C. Inactivation of a histone methyltransferase by mutations in human cancers Cancer Res. 63 2003 7619 7623
85. L. He RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis Cancer Res. 58 1998 4238 4244
86. Steele-Perkins G. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily Genes Dev. 15 2001 2250 2262
87. Hamamoto R. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells Nat. Cell Biol. 6 2004 731 740
88. Tsuge M. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5? flanking region of SMYD3 is a risk factor for human cancers Nat. Genet. 37 2005 1104 1107
89. Y. Shi Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 Cell 119 2004 941 953
90. Forneris F. Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process FEBS Lett. 579 2005 2203 2207
91. Bannister A.J., Kouzarides T. Reversing histone methylation Nature 436 2005 1103 1106
92. Metzger E. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription Nature 437 2005 436 439
93. McBride A.E., Silver P.A. State of the arg: protein methylation at arginine comes of age Cell 106 2001 5 8
94. Lee J.H. PRMT7, a new protein arginine methyltransferase that synthesizes symmetric dimethylarginine J. Biol. Chem. 280 2005 3656 3664
95. J. Lee PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family J. Biol. Chem. 280 2005 32890 32896
96. Smith W.A. Arginine methylation of RNA helicase a determines its subcellular localization J. Biol. Chem. 279 2004 22795 22798
97. Mowen K.A. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription Cell 104 2001 731 741
98. Komyod W. Are STATS Arginine-methylated? J. Biol. Chem. 280 2005 21700 21705
99. W. An Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53 Cell 117 2004 735 748
100. W. Xu Acetylation and methylation in nuclear receptor gene activation Methods Enzymol. 364 2003 205 223
101. Chen D. Regulation of transcription by a protein methyltransferase Science 284 1999 2174 2177
102. Schurter B.T. Methylation of histone H3 by coactivator-associated arginine methyltransferase 1 Biochemistry 40 2001 5747 5756
103. Bauer U.M. Methylation at arginine 17 of histone H3 is linked to gene activation EMBO Rep. 3 2002 39 44
104. W. Xu A transcriptional switch mediated by cofactor methylation Science 294 2001 2507 2511
105. Chevillard-Briet M. Control of CBP co-activating activity by arginine methylation EMBO J. 21 2002 5457 5466
106. Pollack B.P. The human homologue of the yeast proteins Skb1 and Hsl7p interacts with Jak kinases and contains protein methyltransferase activity J. Biol. Chem. 274 1999 31531 31542
107. Branscombe T.L. PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins J. Biol. Chem. 276 2001 32971 32976
108. J. Rho Prmt5, which forms distinct homo-oligomers, is a member of the protein-arginine methyltransferase family J. Biol. Chem. 276 2001 11393 11401
109. Fabbrizio E. Negative regulation of transcription by the type II arginine methyltransferase PRMT5 EMBO Rep. 3 2002 641 645
110. S. Pal Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes Mol. Cell. Biol. 24 2004 9630 9645
111. Chie L. A protein methyl transferase, PRMT5, selectively blocks oncogenic ras-p21 mitogenic signal transduction Ann. Clin. Lab. Sci. 33 2003 200 207
112. Nowak S.J., Corces V.G. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation Trends Genet. 20 2004 214 220
113. Pascreau G. Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis Prog. Cell Cycle Res. 5 2003 369 374
114. Ducat D., Zheng Y. Aurora kinases in spindle assembly and chromosome segregation Exp. Cell Res. 301 2004 60 67
115. Katayama H. The Aurora kinases: role in cell transformation and tumorigenesis Cancer Metastasis Rev. 22 2003 451 464
116. S. Sen Amplification/overexpression of a mitotic kinase gene in human bladder cancer J. Natl. Cancer Inst. 94 2002 1320 1329
117. Dutertre S., Prigent C. Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint Mol. Interv. 3 2003 127 130
118. Miao X. Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma Cancer Res. 64 2004 2680 2683
119. Davie J.R. MSK1 and MSK2 mediate mitogen- and stress- induced phosphorylation of histone H3: a controversy resolved Sci. STKE 2003 2003 PE33
120. Lo W.S. Snf1-a histone kinase that works in concert with the histone acetyltransferase Gcn5 to regulate transcription Science 293 2001 1142 1146
121. Egger G. Epigenetics in human disease and prospects for epigenetic therapy Nature 429 2004 457 463
122. Brueckner B., Lyko F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy Trends Pharmacol. Sci. 25 2004 551 554
123. Lund A.H., van Lohuizen M. Epigenetics and cancer Genes Dev. 18 2004 2315 2335
124. Prokhortchouk E., Hendrich B. Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs? Oncogene 21 2002 5394 5399
125. Stirzaker C. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors Cancer Res. 57 1997 2229 2237
126. Hiltunen M.O. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma Int. J. Cancer 70 1997 644 648
127. Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer Cancer Res. 57 1997 3347 3350
128. Herman J.G. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma Proc. Natl. Acad. Sci. U. S. A. 95 1998 6870 6875
129. Issa J.P. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
130. Saunthararajah Y. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease Blood 102 2003 3865 3870
131. Jahangeer S. beta-Adrenergic receptor induction in HeLa cells: synergistic effect of 5-azacytidine and butyrate Biochem. Biophys. Res. Commun. 108 1982 1434 1440
132. Ginder G.D. Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate Proc. Natl. Acad. Sci. U. S. A. 81 1984 3954 3958
133. Claus R., Lubbert M. Epigenetic targets in hematopoietic malignancies Oncogene 22 2003 6489 6496
134. Brueckner B. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases Cancer Res. 65 2005 6305 6311
135. Juttermann R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation Proc. Natl. Acad. Sci. U. S. A. 91 1994 11797 11801
136. McLaughlin F., La Thangue N.B. Histone deacetylase inhibitors open new doors in cancer therapy Biochem. Pharm. 68 2004 1139 1144
137. O'Connor O.A. Developing new drugs for the treatment of lymphoma Eur J Haematol Suppl 66 2005 150 158
138. Plumb J.A. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101 Mol. Cancer Ther. 2 2003 721 728
139. Plumb J.A. Epigenetic approaches to cancer therapy Biochem. Soc. Trans. 32 2004 1095 1097
140. Phiel C.J. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J. Biol. Chem. 276 2001 36734 36741
141. Gottlicher M. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J. 20 2001 6969 6978
142. Johannessen C.U. Mechanisms of action of valproate: a commentatory Neurochem. Int. 37 2000 103 110
143. Chavez-Blanco A. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study Mol. Cancer 4 2005 22
144. Martinez-Balbas M.A. Regulation of E2F1 activity by acetylation EMBO J. 19 2000 662 671
145. W. Gu, Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain Cell 90 1997 595 606
146. Chan H.M. Acetylation control of the retinoblastoma tumour-suppressor protein Nat. Cell Biol. 3 2001 667 674
147. Nimmanapalli R. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells Blood 101 2003 3236 3239
148. Jang E.R. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen Oncogene 23 2004 1724 1736
149. Zhu W.G., Otterson G.A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells Curr. Med. Chem. Anti-Canc. Agents 3 2003 187 199
150. Cheng D. Small molecule regulators of protein arginine methyltransferases J. Biol. Chem. 279 2004 23892 23899
151. Balasubramanyam K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription J. Biol. Chem. 279 2004 51163 51171
152. Balasubramanyam K. Small molecule modulators of histone acetyltransferase p300 J. Biol. Chem. 278 2003 19134 19140
153. Stimson L. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity Mol. Cancer Ther. 4 2005 1521 1532
154. Balasubramanyam K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression J. Biol. Chem. 279 2004 33716 33726
155. Gadea B.B., Ruderman J.V. Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts Mol. Biol. Cell 16 2005 1305 1318
156. Sessa F. Mechanism of Aurora B activation by INCENP and inhibition by hesperadin Mol. Cell 18 2005 379 391
157. Park J.H. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation Clin. Cancer Res. 10 2004 5271 5281
158. E. Hu Identification of novel isoform-selective inhibitors within class I histone deacetylases J. Pharmacol. Exp. Ther. 307 2003 720 728
159. Seligson D.B. Global histone modification patterns predict risk of prostate cancer recurrence Nature 435 2005 1262 1266
160. Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev. 18 2004 2046 2059
161. Yang X.J. Multisite protein modification and intramolecular signaling Oncogene 24 2005 1653 1662